By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Amylon Therapeutics 

Zernikedreef 9

Leiden    2333CR   Netherlands
Phone: n/a Fax: n/a


SEARCH JOBS

Amylon Therapeutics targets CNS disorders through an ultra-genetics approach, focusing on rare genetic disorders that can serve as a possible gateway to more frequently occurring indications. The anti-amyloid technology of Amylon allows a focus on different disorders, with a primary focus on HCHWA-D and CAA. Amylon is led by founder Thomas de Vlaam, complemented by a scientific board of experienced scientists and biotech veterans. As a spin-off from the NASDAQ traded ProQR Therapeutics, Amylon enjoys a wealth of knowledge and experience through its shareholders and network.

LEADERSHIP:

Founder and CEO: Thomas de Vlaam


Key Statistics


Email:
Ownership: Private

Web Site: Amylon Therapeutics
Employees:
Symbol: 
 



Industry
Pharmaceutical






Company News
//-->